BioDelivery Sciences Announces BELBUCA® Patent Litigation Settlement Agreement with Teva

- February 6th, 2018

BioDelivery Sciences (NASDAQ:BDSI) announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. that resolves BDSI’s previously reported BELBUCA® (buprenorphine) buccal film (CIII), patent litigation against Teva pending in the United States District Court for the District of Delaware. As quoted in the press release: “We … Continued

BioDelivery Sciences (NASDAQ:BDSI) announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. that resolves BDSI’s previously reported BELBUCA® (buprenorphine) buccal film (CIII), patent litigation against Teva pending in the United States District Court for the District of Delaware.

As quoted in the press release:

“We are pleased to have resolved our BELBUCA lawsuit with Teva.  We believe that this settlement, together with our previously announced settlement of the lawsuit with Teva regarding BUNAVAIL®, provide additional certainty around our patent portfolio and the future potential for our two commercialized products,” said Scott Plesha, President of BioDelivery Sciences.  “Importantly, settling these lawsuits allows us to avoid future litigation costs and thus preserve capital resources.”

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

 
Read our FREE outlook report below!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply